Press Releases

 
Press Releases
  Date Title and Summary View
Mar 16, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles (UCLA) and a renowned cancer researcher, h...
Mar 14, 2017
50 Percent of Patients in Ongoing Complete Remission with Duration Ranging from 7+ to 24+ months Study Demonstrates that IL-15 Blood Levels and CAR T-Cell Expansion Correlate to an Improved Clinical Outcome Conducted Under a Cooperative Research and Development Agre...
Mar 8, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the closing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.00 per share, as well as the exercise in full of the underwriters' option to purchase...
Mar 6, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at two investor conferences in March 2017: • Cowen 37th Annual Health Care Conference ...
Mar 5, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc., (Nasdaq:KITE) today announced that Richard L. Wang, Ph.D. will be appointed Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd, the company's 50/50 owned joint venture in China with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (60019...
Mar 2, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.00 per share. The offering is expected to close on or about March 7, 2017, subject to...
Mar 2, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today announced the commencement of an underwritten public offering of 4,750,000 shares of its common stock. In addition, Kite has granted the underwriters of the offering a 30-day option to purchase up to an additional 712,500 shares of its...
Feb 28, 2017
Strong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017 ...
Feb 28, 2017
Met Primary Endpoint of Objective Response Rate (p...
Feb 27, 2017
Conference Call and Webcast Scheduled for 6:00 AM PT/9:00 AM ET SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017, prior to the open of the market. The ...
Page:
1
... NextLast
= add release to Briefcase